HomeCompareCSPHF vs JEPI

CSPHF vs JEPI: Dividend Comparison 2026

CSPHF yields 198.02% · JEPI yields 8.56%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPHF wins by $112.67M in total portfolio value
10 years
CSPHF
CSPHF
● Live price
198.02%
Share price
$1.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$112.70M
Annual income
$56,534,499.65
Full CSPHF calculator →
JEPI
JPMorgan Equity Premium Income ETF
● Live price
8.56%
Share price
$55.65
Annual div
$4.76
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29.3K
Annual income
$1,573.67
Full JEPI calculator →

Portfolio growth — CSPHF vs JEPI

📍 CSPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPHFJEPI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPHF + JEPI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPHF pays
JEPI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPHF
Annual income on $10K today (after 15% tax)
$16,831.68/yr
After 10yr DRIP, annual income (after tax)
$48,054,324.70/yr
JEPI
Annual income on $10K today (after 15% tax)
$727.38/yr
After 10yr DRIP, annual income (after tax)
$1,337.62/yr
At 15% tax rate, CSPHF beats the other by $48,052,987.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPHF + JEPI for your $10,000?

CSPHF: 50%JEPI: 50%
100% JEPI50/50100% CSPHF
Portfolio after 10yr
$56.36M
Annual income
$28,268,036.65/yr
Blended yield
50.15%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPHF buys
0
JEPI buys
0
No recent congressional trades found for CSPHF or JEPI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPHFJEPI
Forward yield198.02%8.56%
Annual dividend / share$2.00$4.76
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$112.70M$29.3K
Annual income after 10y$56,534,499.65$1,573.67
Total dividends collected$106.15M$12.0K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: CSPHF vs JEPI ($10,000, DRIP)

YearCSPHF PortfolioCSPHF Income/yrJEPI PortfolioJEPI Income/yrGap
1← crossover$30,502$19,801.98$11,276$855.74+$19.2KCSPHF
2$89,086$56,448.56$12,675$926.02+$76.4KCSPHF
3$249,403$154,080.96$14,207$999.01+$235.2KCSPHF
4$670,003$403,142.26$15,878$1,074.57+$654.1KCSPHF
5$1,729,066$1,012,162.66$17,697$1,152.57+$1.71MCSPHF
6$4,291,289$2,441,188.37$19,674$1,232.87+$4.27MCSPHF
7$10,253,990$5,662,310.92$21,815$1,315.29+$10.23MCSPHF
8$23,616,660$12,644,890.45$24,131$1,399.68+$23.59MCSPHF
9$52,487,868$27,218,041.68$26,630$1,485.86+$52.46MCSPHF
10$112,696,518$56,534,499.65$29,323$1,573.67+$112.67MCSPHF

CSPHF vs JEPI: Complete Analysis 2026

CSPHFStock

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Full CSPHF Calculator →

JEPIETF

The fund seeks to provide the majority of the returns associated with its primary benchmark, the Standard & Poor's 500 Total Return Index (S&P 500 Index), while exposing investors to less risk through lower volatility and still offering incremental income. Under normal circumstances, the fund invests at least 80% of its assets in equity securities. It may also invest in other equity securities not included in the S&P 500 Index.

Full JEPI Calculator →
📬

Get this CSPHF vs JEPI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPHF vs SCHDCSPHF vs OCSPHF vs KOCSPHF vs MAINCSPHF vs JEPQCSPHF vs XYLDCSPHF vs DIVOCSPHF vs QYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.